GSK launches Singapore laboratory

Kovac, Matt
March 2007
ICIS Chemical Business;3/26/2007, Vol. 2 Issue 59, p34
Trade Publication
The article reports on the opening of a medicinal chemical laboratory by Glaxosmithkline at its research and development facility in Singapore. The move is part of an effort to boost research into neurodegenerative disorders. The company says it hopes to identify the critical chemical for a drug to fight disorders such as Alzheimer's and schizophrenia by the end of 2007. The new laboratory will combine both biology research and chemistry research in the same facility.


Related Articles

  • Reflections on the past 25 years. Gago, Federico // Journal of Computer-Aided Molecular Design;Jan2012, Vol. 26 Issue 1, p45 

    In this article the author discusses the changes in the computational laboratories of drug design and molecular simulations. He stresses the availability of programs and servers that perform multitasks for free. The author states about the existence of hyperlinked databases for...

  • GlaxoSmithKline Tracks R&D Performance. Ritter, Amy // BioPharm International;Mar2012, Vol. 25 Issue 3, p13 

    The article reports that the 12% up return from 11% in 2011 was tracked by GlaxoSmithKline (GSK) in its research and development (R&D) performance in the fourth quarter and full year 2011 earnings report released on February 7, 2012.

  • Orexin Receptor Antagonists: Medicinal Chemistry and Therapeutic Potential. Roecker, Anthony J.; Coleman, Paul J. // Current Topics in Medicinal Chemistry;Jul2008, Vol. 8 Issue 11, p977 

    Actelion Pharmaceuticals achieved clinical proof-of-concept for the treatment of insomnia in 2007 with the release of Phase II data on Almorexant, a potent dual (OX1R/OX2R) orexin receptor antagonist. GlaxoSmithKline also released clinical efficacy data on an orexin receptor antagonist in 2007...

  • University of York: Genetic discovery unlocks biosynthesis of medicinal compound in poppy.  // Biomedical Market Newsletter;6/1/2012, Vol. 21, p1 

    The article reports that scientists at the University of York, York, England and GlaxoSmithKline (GSK) have discovered a complex gene cluster responsible for the synthesis of the medicinal compound noscapine. It is expected that the discovery will reveal the unknown biochemical pathway for...

  • Thermo Fisher Scientific's NEW DIVISION IS ALL ABOUT PORTABILITY. Baginski, Caren // Functional Ingredients;Jan2011, Issue 104, p57 

    The article profiles the portable optical analysis division of Thermo Fisher Scientific, a manufacturer of handheld instruments that identify and authenticate chemicals and raw materials without the aid of a scientist. A discussion of the mechanisms by which a TruScan handheld scanner that is...

  • Closing the Gap between Centralized and Decentralized Compound Management Approaches. Andreae, Marc R. M.; Steiner, Thomas; Hueber, Matthieu; Schopfer, Ulrich; Smith, Robert; Igo, Debra; Cantrell, Daryl; Hohos, Aaron; Kiwanuka, Andrew // Combinatorial Chemistry & High Throughput Screening;Dec2008, Vol. 11 Issue 10, p825 

    The demand for organized storage concepts to maintain, collect and distribute compounds has grown not only at pharmaceutical companies, but also at smaller research organizations and academic laboratories where there is the demand to store and retrieve substances systematically. However, budget...

  • Finding the sweet spot: the role of nature and nurture in medicinal chemistry. Hann, Michael M.; Keserü, György M. // Nature Reviews Drug Discovery;May2012, Vol. 11 Issue 5, p355 

    Given its position at the heart of small-molecule drug discovery, medicinal chemistry has an important role in tackling the well-known productivity challenges in pharmaceutical research and development. In recent years, extensive analyses of successful and failed discovery compounds and drug...

  • NMT Opens New Facility.  // American Ceramic Society Bulletin;Jun2006, Vol. 85 Issue 6, p6 

    The article reports on Singapore-based NanoMaterials Technology Pte. Ltd.'s opening of a $1.54-million facility. Pharmaceutical and chemical laboratories have been formed and the research and development staff will be increased. The company's patented high-gravity controlled precipitation...

  • Evonik Boosts R&D Center in India. Scott, Alex // Chemical Week;1/7/2008, Vol. 170 Issue 1, p40 

    The article reports on the expansion of the research and development (R&D) center of chemical company Evonik Industries in Mumbai, India. The expansion includes a doubling of laboratory space for pharmaceutical-related activities to 1,200 cubic meters. Evonik's activities at the laboratory...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics